GlassScriptPhysician profile
Ryan N Chauvin
NPI 1417158536
$2,575.13
in general payments reported to CMS, 2019-2025
22 companies · $614 in 2025
The $614 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $192 · 2021: $376 · 2022: $463 · 2023: $229 · 2024: $462 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $892.20 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Genzyme Corporation | $282.89 | 2024-2025 | |
| Janssen Biotech, INC. | $248.50 | 2019-2024 | Simponi Aria, Stelara, Simponi |
| Celgene Corporation | $223.99 | 2022-2024 | Zeposia |
| Pfizer INC. | $155.24 | 2020-2025 | |
| Gilead Sciences, INC. | $151.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.26 | 2020-2024 | Entyvio |
| Boston Scientific Corporation | $66.05 | 2022-2024 | Orca, Resolution Clip |
| Ironwood Pharmaceuticals, INC | $63.71 | 2020-2022 | |
| Apollo Endosurgery US INC | $60.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.34 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $44.42 | 2025 | Iqirvo |
| Allergan, INC. | $41.41 | 2019-2020 | |
| Medtronic, INC. | $32.30 | 2024 | Interstim |
| Mallinckrodt Hospital Products INC. | $30.69 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $28.80 | 2019 | |
| Intercept Pharmaceuticals, INC. | $24.51 | 2020-2022 | |
| Celltrion USA INC. | $21.28 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $18.48 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $16.84 | 2021 | |
| Merck Sharp & Dohme LLC | $12.05 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Chauvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.